PTGS2 and neoplasm: Targeting the suppression of mito-COX-2 and selective induction of SIRT3 could inhibit p-Drp1Ser616-driven mitochondrial fission, to induce apoptosis and sensitize HCC cells to multipattern anti-tumor therapy.